ArticleOrphanet journal of rare diseases2026
Patient-driven surveys of mucopolysaccharidoses revealed patient-reported outcomes in the Japan MPS patient and family group.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundJapan Mucopolysaccharidoses (MPS) Patient and Family Group (J-MPS) was founded in 1986. It is the largest patient group for all types of MPS in Japan and now includes some of the patients with lysosomal storage diseases. Patients receive medical care but suffer from the daily progression of symptoms, holding a different assessment of treatment effectiveness than that considered by the medical professionals. This study summarises the annual reports of the society and the results of periodic surveys conducted by their own. The 20-year annual reports are based on J-MPS membership records since 2005. The three questionnaire surveys were planned, designed, and conducted by the patient association own. Survey I was conducted mainly about treatment and activities of daily living with MPS I, II, IVA, and VI for which ERTs are available. Survey II asked about current symptoms and medical care with MPS IIIA and IIIB. Survey III was focused on ocular complications and skeletal symptoms with all types of MPS.
resultsMPS II is the most common type of membership, and the average age of members is gradually increasing over the year. In MPS, age at diagnosis has decreased compared to previous surveys. Even though enzyme replacement therapy and hematopoietic stem cell transplantation have improved symptoms, there is a slight discrepancy between improvement and patient satisfaction. The degree of need for assistance in life varies with the disease type. Decreased bone mineral density and retinal pigmentary degeneration may be underestimated.
conclusionsThis research is not physician-led evaluations, but patient-driven surveys, which is significant in that it focuses on the problems faced by patients and their families in the current era when enzyme replacement therapies are available. Coordination among patients, families, health care providers, and physicians is important to improve patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.